ArticleFrontiers in aging neuroscience2026
Effects of transmembrane protein 106B genetic variations on disease progression in Parkinson's disease.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transmembrane protein 106B ( Methods: We longitudinally followed 241 PD patients and genotyped their single nucleotide polymorphism (SNP) of rs3173615. Patients were categorized according to rs3173615 genotypes into GG (major allele homozygotes), GC (heterozygotes), and CC (minor allele homozygotes) groups. All patients completed clinical evaluations and neuropsychological tests at baseline and every follow-up. Linear mixed-effects models were adopted to evaluate the association between rs3173615 genotypes and longitudinal disease progression in PD. Results: At baseline, both the GG and GC groups presented less severe excessive daytime sleepiness than the CC group, and no association between the remaining clinical characteristics and the genotypes of rs3173615 was observed among the three groups. Longitudinally, compared with the CC group, the GC group manifested a significantly faster exacerbation of depression, visuospatial function and quality of life (QoL), and the GG group showed the same tendency as the GC group, though without statistical significance. Conclusion:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.